Related Experiment Video
Updated: May 15, 2026
Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
Riluzole for acute traumatic spinal cord injury: a promising neuroprotective treatment strategy
Jefferson R Wilson1, Michael G Fehlings1
1Department of Surgery, Division of Neurosurgery and Spinal Program, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.
Background:
Over the years, understanding of the specific secondary injury mechanisms that follow traumatic spinal cord injury (SCI) has improved. These pathologic mechanisms collectively serve to increase the extent of neural tissue injury, reducing prospects for neurologic recovery. An enhanced understanding of the pathobiology of SCI has permitted investigation of therapies targeting specific elements of this pathologic cascade. It is now known that the continuous posttraumatic activation of neuronal voltage-gated sodium ion channels leads to increased rates of cell death through the development of cellular swelling, acidosis, and glutaminergic excitotoxicity. The objective herein is to provide an update regarding the current status of the potential neuroprotective drug riluzole in the treatment of traumatic SCI.
Methods:
Narrative review and summary paper.
Results:
Riluzole is a sodium channel-blocking benzothiazole anticonvulsant drug that is approved by the U.S. Food and Drug Administration for the treatment of amyotrophic lateral sclerosis and has shown efficacy in preclinical models of SCI in reducing the extent of sodium and glutamate mediated secondary injury. This drug is currently under early stages of clinical investigation in SCI and shows promise as an acute neuroprotective therapy in this context.
Conclusion:
This article reviews the biologic rationale, existing preclinical evidence, and emerging clinical data for riluzole in the treatment of traumatic SCI.
Insights
Riluzole, a sodium channel blocker, shows promise for treating traumatic spinal cord injury (SCI). Early clinical data suggest it may reduce secondary injury and improve outcomes in SCI patients.
Area of Science:
- Neuroscience
- Pharmacology
- Traumatology
Background:
- Traumatic spinal cord injury (SCI) involves complex secondary injury mechanisms.
- Continuous activation of sodium channels contributes to cell death via swelling, acidosis, and excitotoxicity.
- Understanding SCI pathobiology enables targeted neuroprotective therapies.
Purpose of the Study:
- To update the status of riluzole as a potential neuroprotective drug for traumatic SCI.
- To review the biological rationale for using riluzole in SCI treatment.
- To summarize preclinical and emerging clinical data for riluzole in SCI.
Main Methods:
- This study is a narrative review and summary paper.
- It synthesizes existing literature on riluzole's efficacy in SCI.
- The review covers biological mechanisms, preclinical findings, and clinical data.
Main Results:
- Riluzole is an FDA-approved anticonvulsant that blocks sodium channels.
- Preclinical SCI models demonstrate riluzole's efficacy in mitigating sodium and glutamate-mediated secondary injury.
- Riluzole is in early clinical investigation for SCI and shows potential as an acute neuroprotective agent.
Conclusions:
- Riluzole presents a promising therapeutic option for acute traumatic SCI.
- The drug's mechanism of action targets key secondary injury pathways.
- Further clinical investigation is warranted to establish riluzole's role in SCI management.
Related Concept Videos
01:25Secondary Spinal Cord Injury llI: Pathophysiology
01:14Spinal Cord Injury ll: Pathophysiology